From the Aiosyn Blog IVDR represents a significant overhaul of regulations requiring more rigorous oversight, clinical validation assessed by a Notified Body, and stricter post-market surveillance (PMS). Aiosyn’s AI-powered...

Nijmegen, the Netherlands –  Aiosyn, a pioneering innovator in AI-powered pathology software for cancer and kidney disease, has announced that its algorithm for mitotic figure counting has achieved CE marking under the In Vitro Diagnostic...

March 2, 2023 - Visiopharm, a leading provider of AI-driven precision pathology software, has announced the launch of a next-generation Ki67 algorithm providing diagnostic decision support for pathologists. The algorithm, which has been cleared...

Ibex: NHS Expands Access to Ibex’s Galen™ Breast and Galen™ Prostate Solutions to 25 Trusts Across the UK Following PathLAKE Plus Consortium Bid Wins Tel Aviv, Israel – March 7, 2023 – Ibex Medical Analytics (Ibex), the leader...

Ibex: Pathology Diagnostics Platform Meets Safety, Quality and Performance Criteria Under EU's New In Vitro Diagnostic Medical Devices Regulation. TEL AVIV, Israel, Feb. 9, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in...

Proscia: Transition to modern digital pathology will improve patient care and enable new research breakthroughs AMSTERDAM and PHILADELPHIA – January 18, 2023 – Proscia®, a leading provider of digital and computational pathology...